From Biogen Call On Aducanumab: Futility Data Set Showed EMERGE Trial By Mar. 20, 2019 Of 49% Opportunity To Complete, ENGAGE Trial 66%; ENGAGE Futility Data Did Not Reduce Clinical Decline
Benzinga Newsdesk